ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)

Status Active, not recruiting

Clinical Trial Summary

The ESPRESSO study is a collection of data from all computerised gastrointestinal histopathology reports in Sweden. This allows us to study risk factors for gastrointestinal disease, as well as the prognosis of gastrointestinal disease. A review of the study has been published here: https://pubmed.ncbi.nlm.nih.gov/30679926/

Clinical Trial Description

The ESPRESSO study constitutes a novel approach to examine the etiology and prognosis of gastrointestinal disease in which histopathology plays a prominent role. Between 2015 and 2017, all pathology departments (n=28) in Sweden were contacted and asked to procure histopathology record data from the gastrointestinal tract (pharynx to anus), liver, gallbladder, and pancreas. For each individual, local histopathology IT personnel retrieved data on personal identity number, date of histopathology, topography (where the biopsy is taken), morphology (biopsy appearance), and where available free text. In total, between 1965 and 2017, histopathology record data were available in 2.1 million unique individuals, but the number of data entries was 6.1 million because more than one biopsy was performed in many of the study participants. Index individuals with histopathology data were matched with up to five controls from the general population. The investigators also identified all first-degree relatives (parents, children, full siblings), and the index individual's first spouse. The total study population consisted of 13.0 million individuals. Data from all the study participants have been linked to Swedish National Healthcare Registers allowing research not only on such aspects as fetal and perinatal conditions and the risk of future gastrointestinal disease but also on the risk of comorbidity and complications (including cancer and death). Furthermore, the ESPRESSO database allows researchers and practitioners to identify diagnoses and disease phenotypes not currently indexed in national registers (including disease precursors). The ESPRESSO database increases the sensitivity and specificity of already-recorded diseases in the national health registers. This paper is an overview of the ESPRESSO database. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06371820
Study type	Observational
Source	Karolinska Institutet
Contact
Status	Active, not recruiting
Phase
Start date	January 1, 1965
Completion date	May 17, 2043

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02541357` - Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery	N/A
Active, not recruiting	`NCT02358122` - Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh	N/A
Active, not recruiting	`NCT02442115` - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Enrolling by invitation	`NCT00943345` - Validation of New Tests for Gastrointestinal (GI) Permeability	Phase 0
Completed	`NCT00612404` - Symptoms and Endoscopic Results in Consideration of Pretreatment	N/A
Completed	`NCT01127711` - Cohort of Swedish Men	N/A
Recruiting	`NCT05712525` - Gut Recovery In Patients Following Surgery
Recruiting	`NCT06094153` - Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune Function	N/A
Recruiting	`NCT05322486` - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Completed	`NCT02486146` - GI Biorepository of Tissue and Bodily Fluids	N/A
Completed	`NCT01816607` - Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
Completed	`NCT00247715` - Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)	N/A
Completed	`NCT00035334` - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis	Phase 2/Phase 3
Recruiting	`NCT06286865` - Improving Quality of ICD-10 Coding Using AI: Protocol for a Crossover Randomized Controlled Trial	N/A
Active, not recruiting	`NCT01037049` - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks	Phase 2
Completed	`NCT03725813` - Study Evaluating the Effect of Person-centred Care for Patients Admitted for Inpatient Care at an Internal Medicine Unit	N/A
Recruiting	`NCT05640401` - Holographic Screens as a Replacement of Monitors During GI Endoscopies	N/A
Completed	`NCT02865564` - Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics	N/A
Completed	`NCT02651857` - Exploratory Study of Upper and Lower Endoscopic Fuse System	N/A
Active, not recruiting	`NCT01984034` - Trial to Assess the Effectiveness of Educational Outreach in Prescription Guidelines	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden) — ESPRESSO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms